Program Layout

Track 1: Frontiers of Immuno-Oncology
IO101: Toward Precision Immuno-Oncology
IO102: Current Progress on Dynamic Target Clusters
IO103: Small Molecules Maximally Optimizing Immuno-Oncology Therapies
IO104: The Current Biomarker Roadmap in Immuno-Oncology
IO105: New Immuno-Oncology Biomarkers Discovery
IO106: New Concepts in Cancer Immunology, Tumor Microenvironmental Perspectiveand Immunotherapy

Track 2: Disruptive Technologies of Immuno-Oncology
IO201: Disruptive Biotech in Discovering Neoantigens and Immunotherapy Modalities
IO202: Smart Technologies in IO
IO203: Engineering of Biospecific and Multispecific Antibodies for IO
IO204: IO Cell Therapy Engineering
IO205: Preclinical Modeling for the Cancer CombinationImmunotherapy
IO206: Successful Case Studies on Combinatorial Cancer Immunotherapy

Track 3: Adoptive Cell Therapy
IO301: New Strategy of Reprogramming Regulatory T Cells
IO302: Emerging Universal CAR T-Cells Targeting Solid Tumors
IO303: Gene/Genome Editing for Adoptive Cell Therapies
IO304: Hot Targeted Antigens for Cell Therapy

Track 4: Microbiome Enhanced Cancer Immunotherapy
IO401: The Microbiome as Next Anti-Cancer Targets
IO402: Gut Microbiome and Cancer Immunotherapy
IO403: Microbiome Engineering for Cancer Immunotherapy
IO404: Microbiome-Based Combination IO